In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.
<Angiomax, effect, heparin>, <Angiomax, effect, warfarin>, <Angiomax, effect, thrombolytics>